Olmesartan_Medoxomil: profile and news

Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share ... Apr 25, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin ... - Yahoo! News (press release)

Forest Laboratories Signs Grants Manager Agreement With Fast Track ... Apr 19, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar® * (olmesartan medoxomil), an angiotensin ... - Market Wire (press release)

Forest Laboratories Fiscal 2007 Guidance Apr 26, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... - Webbolt Business News,

Other information

Indication
For the treatment of hypertension

Pharmacology
Olmesartan Medoxomil, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Olmesartan Medoxomil does not have an active metabolite or possess uricosuric effects.

Mechanism Of Action
Olmesartan Medoxomil competes with angiotensin II for binding at the also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decrease in systemic vascular resistance.

Drug Category
Antihypertensive Agents; ATC:C09CA08

Brand Names/Synonyms
Benicar; CS 866; Olmesartan; Olmesartan Medoximil; Olmesartan Medoxomil; Olmetec

Dosage Forms
~13 hours

Absorption
Bioavailability is about 26%

Interactions
Drug Interactions for Olmesartan Medoxomil:

No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)₃/Mg(OH)₂]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce or are metabolized by those enzymes are not expected.

Chemical IUPAC Name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-imidazole-4-carboxylate

Chemical Formula
C29H30N6O6

Half Life
~13 hours

Drug Type
Approved Drug

# Accession No
APRD00223

CAS Registry Number
144689-63-4